Search hospitals > New York > Albany

Women's Cancer Care Associates, LLC

Claim this profile
Albany, New York 12208
Global Leader in Ovarian Cancer
Global Leader in Fallopian Tube Cancer
Conducts research for Uterine Cancer
Conducts research for Peritoneal Cancer
Conducts research for Ovarian Carcinoma
53 reported clinical trials
4 medical researchers
Photo of Women's Cancer Care Associates, LLC in AlbanyPhoto of Women's Cancer Care Associates, LLC in AlbanyPhoto of Women's Cancer Care Associates, LLC in Albany

Summary

Women's Cancer Care Associates, LLC is a medical facility located in Albany, New York. This center is recognized for care of Ovarian Cancer, Fallopian Tube Cancer, Uterine Cancer, Peritoneal Cancer, Ovarian Carcinoma and other specialties. Women's Cancer Care Associates, LLC is involved with conducting 53 clinical trials across 63 conditions. There are 4 research doctors associated with this hospital, such as Emese Zsiros, JOYCE BARLIN, Shashikant B. Lele, and Peter Frederick, MD.

Area of expertise

1Ovarian Cancer
Global Leader
Women's Cancer Care Associates, LLC has run 29 trials for Ovarian Cancer. Some of their research focus areas include:
Stage IV
Stage III
Stage II
2Fallopian Tube Cancer
Global Leader
Women's Cancer Care Associates, LLC has run 23 trials for Fallopian Tube Cancer. Some of their research focus areas include:
Stage III
Stage IV
Stage II

Top PIs

Clinical Trials running at Women's Cancer Care Associates, LLC

Ovarian Cancer
Endometrial Cancer
Uterine Cancer
Endometrial Adenocarcinoma
Uterine Carcinosarcoma
Fallopian Tube Cancer
Cancer
Peritoneal Neoplasm
Genital Diseases
Endometrioid Carcinoma
Image of trial facility.

Mirvetuximab + Bevacizumab

for Ovarian Cancer

GLORIOSA is a Phase 3 multicenter, open label study designed to evaluate the safety and efficacy of mirvetuximab Soravtansine + Bevacizumab as maintenance therapy in participants with platinum-sensitive ovarian, primary peritoneal or fallopian tube cancers with high folate receptor-alpha (FRα) expression.
Recruiting2 awards Phase 3
Image of trial facility.

Mirvetuximab Soravtansine

for Ovarian Cancer

The purpose of this study is to evaluate the incidence rate and severity of prespecified mirvetuximab soravtansine (MIRV)-related ocular treatment-emergent adverse events (TEAEs) and assess prophylaxis strategies in all participants (symptomatic and asymptomatic) undergoing prospective ophthalmic evaluation with recurrent ovarian cancer (participants with either platinum-sensitive ovarian cancer \[PSOC\] or platinum-resistant ovarian cancer \[PROC\]) with high folate receptor alpha (FRα) expression.
Recruiting1 award Phase 2
Image of trial facility.

Surgical Procedures

for Reducing Ovarian Cancer Risk

This clinical trial evaluates how well two surgical procedures (bilateral salpingectomy and bilateral salpingo-oophorectomy) work in reducing the risk of ovarian cancer for individuals with BRCA1 mutations. Bilateral salpingectomy involves the surgical removal of fallopian tubes, and bilateral salpingo-oophorectomy involves the surgical removal of both the fallopian tubes and ovaries. This study may help doctors determine if the two surgical procedures are nearly the same for ovarian cancer risk reduction for women with BRCA1 mutations.
Recruiting1 award N/A

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Women's Cancer Care Associates, LLC?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security